prof. dr. E. (Edo) Vellenga

Professor

prof. dr. E. (Edo) Vellenga
Telephone:
E-mail:
e.vellenga umcg.nl

Research

Publications
  1. Eight versus four induction cycles of Carfilzomib, Thalidomide and Low-dose Dexamethasone: the Carthadex trial

    Wester, R., Zweegman, S., Van der Holt, B., Jose, K. M., Vellenga, E., van Marwijk-Kooy, M., Asselbergs, E., de Weerdt, O., Minnema, M., Lonergan, S., Palumbo, A., Broijl, A. & Sonneveld, P., Oct-2019, In : Clinical lymphoma myeloma & leukemia. 19, 10, p. E220-E221 2 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  2. Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern

    Berger, G., Gerritsen, M., Yi, G., Koorenhof-Scheele, T. N., Kroeze, L. I., Stevens-Kroef, M., Yoshida, K., Shiraishi, Y., van den Berg, E., Schepers, H., Huls, G., Mulder, A. B., Ogawa, S., Martens, J. H. A., Jansen, J. H. & Vellenga, E., 2019, In : Blood. 3, 20, p. 3111-3122 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

    Broijl, A., Kersten, M. J., Alemayehu, W. G., Levin, M. D., de Weerdt, O., Vellenga, E., Meijer, E., Wittebol, S., Tanis, B. C., Cornelisse, P. B., Stevens-Kroef, M., Bos, G. M. J., Wijermans, P. W., Lokhorst, H. & Sonneveld, P., 31-Mar-2016, In : Haematologica. 101, 4, p. e149-e152

    Research output: Contribution to journalLetterAcademicpeer-review

  4. Protein quality control in the nucleolus safeguards recovery of epigenetic regulators after heat shock

    Azkanaz, M., Rodríguez López, A., de Boer, B., Huiting, W., Angrand, P-O., Vellenga, E., Kampinga, H. H., Bergink, S., Martens, J. H., Schuringa, J. J. & van den Boom, V., 14-Jun-2019, In : eLife. 8, 27 p., 45205.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (497) »

View graph of relations

ID: 156947